Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)
Status:
Unknown status
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and the efficacy of cladribine, high-dose
cytarabine and idarubicin in the treatment of patients with relapsed acute myeloid leukemia.